Download App

Log in to access Online Inquiry
Company Overview More
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRα), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRα product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
CEO: Enyedy, Mark Joseph
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > IMGN ImmunoGen > Detailed Quotes

IMGN ImmunoGen

3.840+0.160+4.35%
Close 05/27 20:00 ET
3.84000.00%
Post Mkt Price 05/27 16:01 ET
High
3.850
Open
3.660
Turnover
11.95M
Low
3.560
Pre Close
3.680
Volume
3.17M
Market Cap
846.86M
P/E(TTM)
Loss
52wk High
7.770
Shares
220.54M
P/E(Static)
Loss
52wk Low
3.360
Float Cap
713.78M
Bid/Ask %
-90.91%
Historical High
45.500
Shs Float
185.88M
Volume Ratio
0.76
Historical Low
0.719
Dividend TTM
--
Div Yield TTM
--
P/B
2.76
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.70%
Amplitude
7.88%
Avg Price
3.770
Lot Size
1
Float Cap
713.78M
Bid/Ask %
-90.91%
Historical High
45.500
Shs Float
185.88M
Volume Ratio
0.76
Historical Low
0.719
Dividend TTM
--
P/B
2.76
Dividend LFY
--
Turnover Ratio
1.70%
Amplitude
7.88%
Avg Price
3.770
Lot Size
1
Price Forecast

No Data

News

Comment